Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The CheckMate 577 study results show double longer disease-free survival with adjuvant nivolumab after neoadjuvant chemoradiotherapy and resection
New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Further work is needed to identify patients who are most at risk of delayed immune-related adverse events to anti-PD1 therapy
In tumours with high mutational burden treated with ICI, improved overall survival associated mainly with mutations in the POLE gene and with defective DNA mismatch repair
Evidence for efficacy is based on the results of KEYNOTE-590 study
New indication concerns first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression
Results from the ASTEROID study with durvalumab after stereotactic body radiotherapy in patients with early stage non-small cell lung cancer
Results from early halted PIPSeN study in chemonaïve patients with non-small cell lung cancer without EGFR or ALK/ROS alterations
Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines
Data with approximately 3 years of follow-up from the KEYNOTE-407 study show improved survival with pembrolizumab added to chemotherapy
Molecular characterisation of tumours with alterations in the PIK3 pathway
More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
